Positive impactCompany

Can AI Solve All Disease? DeepMind Co-Founder Demis Hassabis Just Raised $5 Billion To Find Out

NDTV Profit 6 hrs ago·17 Nov 2026, 3:44 pm

Demis Hassabis, co-founder of DeepMind, has launched a new venture called Isomorphic to apply artificial intelligence to drug discovery. The company has secured $5 billion in funding to develop its IsoDDE platform, which uses advanced simulation models to study biological systems and design new drug molecules. This significant financial backing signals strong confidence in using AI to tackle complex health challenges.

For investors, this move highlights the growing potential of AI in the biotechnology sector. If successful, it could revolutionize how new medicines are discovered, potentially leading to faster and more efficient treatments for various diseases. The project aims to bridge the gap between computational power and biological complexity, a field known as computational biology.

What to watch next is the progress of the IsoDDE platform. Investors should look for updates on the company's ability to identify viable drug candidates and its partnerships with pharmaceutical firms. While the long-term impact remains uncertain, the venture represents a major step toward integrating AI into healthcare, which could have far-reaching implications for the industry.

Key takeaways

  • Category: Company.
  • AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NDTV Profit.

More Company news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.